Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/48649
Campo DC Valoridioma
dc.contributor.authorRodriguez-Gallego, C.en_US
dc.contributor.authorArnaiz-Villena, A.en_US
dc.contributor.authorCorell, A.en_US
dc.contributor.authorManzanares, J.en_US
dc.contributor.authorTimon, M.en_US
dc.contributor.authorPacheco, A.en_US
dc.contributor.authorRegueiro, J. R.en_US
dc.date.accessioned2018-11-23T23:43:53Z-
dc.date.available2018-11-23T23:43:53Z-
dc.date.issued1994en_US
dc.identifier.issn0009-9104en_US
dc.identifier.urihttp://hdl.handle.net/10553/48649-
dc.description.abstractA 2-year-old female with important signs of immune response failure against virus, bacteria, fungi and protozoa and no obvious humoral or lymphocyte phenotypical defect was studied. Both peripheral blood mononuclear cells and IL-2-dependent T cell lines derived from the patient showed a severe selective T cell activation impairment via CD2, CD3 and CD43; however, this defect was reversible with the addition of either IL-2, or phorbol myristate acetate (PMA) or anti-CD28 antibodies. Concordantly, the induction of IL-2 (and, in part, IL-3 and IL-4) messenger RNA was severely reduced in stimulated T cells, but that of other cytokines was either normal (IL-5) or only slightly diminished (interferon-gamma (IFN-gamma)). It is concluded that an activation T cell defect exists previous to protein kinase C (PKC) and between membrane receptors and the activation pathway of certain response genes encoding for interleukins involved in proliferation (i.e. IL-2, IL-3 and IL-4), but not of others (i.e. IL-5). The use of T cell lines from human T lymphocyte activation deficiencies allows dissection of T cell pathology and the corresponding physiological pathways. In the present description, there is an evident independence of the CD28 T cell activation pathway from those induced through CD2 or CD3, and the differential gene regulation of the different interleukins.en_US
dc.languageengen_US
dc.relation.ispartofClinical and experimental immunology (Print)en_US
dc.sourceClinical and Experimental Immunology[ISSN 0009-9104],v. 97, p. 386-391 (Septiembre 1994)en_US
dc.subject32 Ciencias médicasen_US
dc.subject3205 Medicina internaen_US
dc.subject.otherCD28 Antigensen_US
dc.subject.otherCytokinesen_US
dc.subject.otherImmunologic Deficiency Syndromesen_US
dc.titlePrimary T lymphocyte immunodeficiency associated with a selective impairment of CD2, CD3, CD43 (but not CD28)-mediated signal transductionen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1111/j.1365-2249.1994.tb06099.xen_US
dc.identifier.scopus0028100859-
dc.contributor.authorscopusid6602114379-
dc.contributor.authorscopusid7102651426-
dc.contributor.authorscopusid7004860935-
dc.contributor.authorscopusid7007128916-
dc.contributor.authorscopusid7004415077-
dc.contributor.authorscopusid57197346439-
dc.contributor.authorscopusid7005510950-
dc.description.lastpage391en_US
dc.description.firstpage386en_US
dc.relation.volume97en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.description.numberofpages6en_US
dc.utils.revisionen_US
dc.date.coverdateSeptiembre 1994en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.scieSCIE-
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptGIR IUIBS: Farmacología Molecular y Traslacional-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-4344-8644-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameRodríguez Gallego, José Carlos-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

5
actualizado el 17-nov-2024

Visitas

62
actualizado el 07-sep-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.